Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Waystream wins new deal from MittNät worth 1.9 MSEK

Waystream, who develops and sells advanced digital infrastructure such as switches and routers for fiber-based broadband networks, has, together with NetNordic Sweden, won a new deal from MittNät. har via sin partner NetNordic fått en ny affär  från MittNät. The majority of the products will be shipped during November 2016 and the total value of the order is 1,900,000 SEK.MittNät was formed about one year ago and today is comprised of city nets from the municipalities of Arvika, Forshaga, Hammarö, Karlstad, Munkfors, Vansbro and Åmål. Using Waystreams MS4000 Ethernet switch, MittNät will

Waystream revises its growth projection and reorganizes Sales department

Waystream, who develops and sells advanced digital infrastructure such as switches and routers for fiber-based broadband networks, is re-organisiing its Sales department. With this reorganisation, all Sales staff will report directly to CEO Johnny Hedlund. The reorganisation is a consequence of the revised annual growth projection.Previously, Waystream has announced that the company has pulled out of Russia and Poland where the sales and marketing conditions have gradually deteriorated during this year. Instead, the company has chosen to focus on the DACH region, i.e. Germany, Austria and

The European Commission Grants VAL001 Orphan Drug Designation for the Treatment of Diffuse Large B-cell Lymphoma

Respiratorius AB (publ.) has received Orphan Drug Designation for its drug candidate VAL001 following a decision by the European Commission. VAL001 will at product launch be included in the EU Community Register of Orphan Medicinal Products.VAL001 is a combination of a HDAC inhibitor (valproic acid) and a steroid (prednisone) and referred to as a pretreatment before chemotherapy (R-CHOP), for the treatment of diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive form of lymphoma, and the most common type of non-Hodgkin lymphoma, which constitute 30% of the patients diagnosed with

Completion of the financial restructuring of EnQuest PLC

THIS ANNOUNCEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR PROSPECTUS EQUIVALENT DOCUMENT. NOTHING HEREIN SHALL CONSTITUTE AN OFFERING OF HIGH YIELD NOTES, RETAIL NOTES OR NEW ORDINARY SHARES. ANY DECISION TO PURCHASE, SUBSCRIBE FOR, OTHERWISE ACQUIRE, SELL OR OTHERWISE DISPOSE OF ANY NEW HIGH YIELD NOTES, EXISTING RETAIL NOTES, AMENDED RETAIL NOTES OR NEW ORDINARY SHARES MUST BE MADE ONLY ON THE BASIS OF THE INFORMATION CONTAINED IN AND INCORPORATED BY REFERENCE INTO THE PROSPECTUS OR THE EXPLANATORY STATEMENT (AS APPLICABLE). COPIES OF THE EXPLANATORY STATEMENT HAVE

Best of breed or single vendor strategy in radiology imaging? Sectra rated #1 in customer satisfaction regardless of approach.

Linköping, Sweden, November 21, 2016 – International medical imaging IT company Sectra  (STO: SECT B) has the highest customer satisfaction in the industry according to a new report from analytics company peer60. The report—Ideal Imaging Configuration: The Tug-of-War Between Enterprise and Best of Breed—shows that Sectra’s customers consistently express the highest satisfaction regardless of IT approach. It also shows that regardless of the customer preference for overall solution architecture, Sectra is the best partner.“Sectra has impressed once again with a very

Cyxone change Certified Adviser

In accordance with the regulations on Nasdaq First North Stockholm, Cyxone uses a Certified Adviser (CA). On the 1st December 2016 Cyxone changed the CA from Consensus Asset Management AB to Erik Penser Bank AB. ContactCyxone AB (publ)Kjell G. Stenberg, CEOTel: 070-716 80 09E-mail: kjell.g.stenberg@cyxone.comAdelgatan 21221 22 Malmöwww.cyxone.com This is information which Cyxone AB (publ) is required to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person for publication on November 21, 2016 at. 09:02

Elocta® approved in Kuwait for the treatment of haemophilia A

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces that the Ministry of Health in Kuwait has approved Elocta® (efmoroctocog alfa), a recombinant human factor VIII Fc-fusion protein with an extended half-life, for the treatment of haemophilia A.  Elocta is the first recombinant factor VIII Fc fusion protein therapy approved for the treatment of haemophilia A in the Middle East region. “The approval of Elocta in Kuwait is an important development for the haemophilia community in the Middle East and brings physicians, and their patients a wider range of

Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study

IBT announces that the second and last planned evaluation of safety data by the independent Data Safety Monitoring Board (DSMB), in the ongoing Phase II clinical study, was performed on November 18th. The DSMB concluded that there were no objections to dose escalation into the final cohort of the smallest  premature babies, who will be dosed with the highest dose of IBT´s drug candidate IBP-9414.  "We are very pleased that we now have 90 of the 120 premature babies recruited and that the study is progressing according to plan. This is another major milestone in the development of a new

Fortum and Ericsson sign collaboration agreement on utilising data centre’s waste heat for district heating

FORTUM CORPORATION PRESS RELEASE 21 NOVEMBER 2016Fortum and Ericsson have signed a collaboration agreement on utilising the waste heat of Ericsson’s data centre, located in the town of Kirkkonummi,Southern Finland, for district heating.Ericsson’s data centre currently generates 10,000 – 15,000 megawatt-hours ofwaste heat annually. The centre’s planned capacity growth in 2017 – 2018 willincrease the amount of waste heat to be recovered with heat pumps by almosttwo-fold.The waste heat from Ericsson’s data centre covers about 20% of the Kirkkonummidistrict heat network’s

Latin American Room Nights Increase by 45 Percent in 2016

Global Wholesaler Reports Encouraging Hotel Growth in the LATAM MarketSAO PAULO – November 21, 2016 – Tourico Holidays , the world’s fastest growing wholesale travel brokerage company, today shared data revealing a 45 percent year-over-year increase in hotel room nights in Latin America. The company is also reporting a 70 percent year-over-year revenue increase generated from the Latin American market in 2016, as inbound bookings surge. The significant growth in Latin American hotel room nights can be attributed to the increased demand from major

Idogen signs agreement with global contract research partner

Idogen AB (”Idogen”) today announces that the company has signed an agreement with Advinus Therapeutics, a leading global contract research organization, for synthesis of zebularine for future pre-clinical and clinical trials. Zebularine is a key component in Idogen’s tolerogenic vaccine. The agreement means that zebularine will be synthesized according to current regulations for GMP (”Good Manufacturing Practice”). This represents an important step taken by Idogen towards a product for clinical trials.Idogen is starting cooperation to synthesis the company’s drug candidate zebularine in

Production update October 2016

Tethys Oil’s share of the production, before government take, fromBlocks 3 and 4 onshore the Sultanate of Oman amounted in October 2016 to379,432 barrels of oil, corresponding to 12,240 barrels of oil per day.Tethys Oil AB, through its wholly owned subsidiary Tethys Oil Block 3and 4 Ltd, has a 30 per cent interest in Blocks 3 and 4. Partners areMitsui E&P Middle East B.V. with 20 per cent and the operator CCEnergy Development S.A.L. (Oman branch) holding the remaining 50 percent.     For further information, please contact Magnus Nordin, Managing Director, phone +46 8 505 947

Hemfosa Fastigheter to invest approximately MSEK 450in properties for Internationella Engelska Skolan

Hemfosa will acquire, develop and invest in three Internationella Engelska Skolan (IES) school properties in Sweden at a value of approximately MSEK 450 and, in parallel, will sign new long-term leases. The investment comprises two new IES schools in Huddinge and Södertälje as well as an expansion of operations in Sundsvall. This represents a further step in Hemfosa’s strategy to develop a close collaboration with established players in the community property sector.One of the property acquisitions with be carried out within the framework of the option that formed part of the acquisition of

NOTICE OF EXTRAORDINARY GENERAL MEETING IN ORGANOCLICK AB (PUBL)

The shareholders of OrganoClick AB (publ), 556704-6908, are hereby convened to a Extraordinary General Meeting (EGM) on Monday 19 December 2016, at 10.00 at OrganoClick AB, Linjalvägen 9, 187 66 Täby. PARTICIPATION Shareholders who wish to attend the EGM shall be registered in OrganoClick’s shareholder register, kept by Euroclear Sweden AB, on the 13th of December 2016, and give notification of attendance to the company by mail to OrganoClick AB (publ), Linjalvägen 9, 187 66 Täby or by email to gunnar.sennstrom@organoclick.com no later tan the 13th of December 2016. Name, personal- or

Cantargia publishes interim report for January – September 2016

Cantargia AB (“Cantargia”) interim report for January – September 2016 is available on the company website (www.cantargia.com/Investors/Reports).Significant events in the third quarter The US patent office granted two of Cantargias patent applications; i.e. the application for the use of IL1RAP as target molecule for antibody-based treatment of solid tumors and as well as the application for IL1RAP as a target for antibody-based treatment of acute lymphoblastic leukemia (ALL). Cantargia raised SEK 250,212.50 through the exercise of warrants of series 2011/2016 by Agneta Svedberg, the

Episurf Medical AB to present at Stora Aktiedagen, held in Stockholm on November 28

Episurf Medical AB will present at Stora Aktiedagen, an investor conference held in Stockholm (Hotel Birger Jarl, Birger Jarlsgatan 61A) on November 28. The company will be represented by CFO Pål Ryfors. For full program and registration, see link. . The presentation will be available on the company’s website.   For more information, please contact: Pål Ryfors, CFO, Episurf Medical Tel: +46 709 62 36 69 Email: pal.ryfors@episurf.com   About Episurf MedicalEpisurf Medical is

Admission of New Ordinary Shares

NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN AND THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. EnQuest PLC, 21 November 2016 Placing and Open Offer Admission of New Ordinary Shares Further to the announcement made by EnQuest PLC ("EnQuest" or the "Company") on 17 November 2016, the Company announces that 356,738,114 New Ordinary Shares being issued pursuant

€50.000 for battery sensor business development from the EU

Insplorion has been allocated €50.000 from the Horizon 2020 SME Instrument phase 1 for immersed market research and business development within the battery market. The Horizon 2020 is an EU Research and Innovation program and the SME Instrument aims to help high-potential small and middle sized enterprises to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition.Unlike previous technical oriented soft funding, Insplorion will use the grant to evaluate the markets, user benefits, and unique value propositions for

Scolty/Crathes First Oil

ENQUEST PLC, 21 November 2016. Scolty/Crathes First Oil First oil from the Scolty/Crathes development was achieved on 21 November 2016. EnQuest CEO Amjad Bseisu said: "EnQuest is pleased to confirm the delivery of first oil from Scolty/Crathes ahead of schedule and under budget, approximately a year after the Field Development Plan ('FDP') was approved and the project was sanctioned. This was the only offshore pure oil FDP approval in the UK North Sea in 2015.  Unit operating costs are expected to be under $15/bbl in the initial peak volume years and production is anticipated to

New boundaries for Block 3 licence area onshore Oman

Tethys Oil AB together with joint venture partners Mitsui E&P MiddleEast B.V. and CC Energy Development S.A.L. (Oman branch) (Operator)have, in accordance with the terms of the Exploration and ProductionSharing Agreement (EPSA) governing the Blocks 3 and 4 licence areaonshore the Sultanate of Oman, agreed new boundaries for the Block 3licence area with the Ministry of Oil and Gas (MOG). The new boundaries exclude a 5,480 square kilometres area in the northeastern part of Block 3, which has been returned to the MOG. After theagreed adjustment the Blocks 3 and 4 licence area

Internationella Engelska Skolan 2016/2017

Interim Report - first quarter (1 July - 30 September 2016)Progress of operations in the quarter · The number of students in the Swedish operation as of 30 September was 21,463 (19,789) · There were around 122,000 registrations of students to the school queues at the end of the quarter, an increase of about 10,000 registrations (9%) compared to June 30th 2016 · Total income per student increased by 2.8% compared to the corresponding quarter of the previous year. As the grant for Lärarlönelyftet, a government initiative to boost teacher salaries introduced on 1 July, first half of

Among antidementia drugs, memantine is associated with the highest risk of pneumonia

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of rivastigmine patches is associated with an increased risk as well. The study found that persons using donepezil or galantamine had the lowest risk of pneumonia. However, persons using memantine or rivastigmine patches had a 1.6 and 1.15 times higher risk of pneumonia, respectively, but no elevated risk was observed among patients using rivastigmine in capsule form. The real risk increase may be even higher, as only

Production and development update

ENQUEST PLC, 21 November 2016.Production and development update EnQuest's Kraken FPSO vessel sail away EnQuest PLC is pleased to announce that following good progress on commissioning the water systems, the Floating, Production, Storage and Offloading ('FPSO') vessel, Armada Kraken for the Kraken field development, is expected to sail away in the coming days, from deep water anchorage off the coast of Singapore, for the North Sea. The journey should complete around mid-January 2017. The Kraken development project remains on course to deliver first oil in H1 2017.  Meanwhile drilling

Etrion and Hitachi High-Technologies Sign Project Finance Agreement to Build 13.2 MW Komatsu Solar Project in Japan

Etrion and Hitachi High-Technologies will build, own and operate the 13.2 MW Komatsu solar project in Japan with financing from Sumitomo Mitsui Trust BankNovember 21, 2016, Miami, Florida and Tokyo, Japan – Etrion Corporation (“Etrion” or the “Company”) (TSX: ETX) (OMX: ETX), a solar independent power producer, announced today the signing of a project finance agreement with Sumitomo Mitsui Trust Bank, Limited (“SuMi Trust”) for the construction of the 13.2-megawatt (“MW”) Komatsu solar project located in the Ishikawa Prefecture of Japan.   Marco A. Northland, Etrion’s Chief Executive

There are no items matching the current filter
There are no more items matching the current filter
Back to top